Short interest for SeaStar Medical Holding gives investors a sense of the degree to which investors are betting on the decline of SeaStar Medical Holding's stock. Short interest data is updated every two weeks.

SeaStar Medical Holding Stock (NASDAQ:ICU), Short Interest Report

SeaStar Medical Holding

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

Super Micro Computer - logo

News

Intraday Update

Markets

Movers

AGBA

AULT

BGLC

BNRG

BTOG

CHRO

EGOX

GSUN

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HUMA

ISPC

MNDR

NFLX

NVFY

Next Technology Holding Inc. - Ordinary Shares

NXTT

OCUL

PARA

RWOD

SBFM

SKYE

SMCI

SPCB

SPCE

SPOT

TELL

TIRX

TPET

TVGN

WISA

Connexa Sports Technologies Inc. - Common Stock

YYAI

ZCMD

Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Penny Stocks

Small Cap

Pre-Market Outlook

Trading Ideas

ACXP

AILE

BRSH

FLGC

NRXP

PLAG

RETO

SELX

SMFL

SNGX

SPEC

TANH

TENX

ZAPP

Shares of  Alcoa Corporation (NYSE: AA) rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter.

Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

ANTX

APLD

ASYS

ATCH

CHEA

CIFR

DHAI

GNSS

HKIT

IGMS

Intelligent Bio Solutions Inc. - Common Stock

INBS

IVVD

JANX

JCSE

LBBB

Larimar Therapeutics, Inc. - Common Stock

LRMR

LUNR

MANU

MDVL

MGIH

MNDY

NSTG

NVIV

PBAX

QBTS

RILY

RNLX

ROOT

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SHOT

SYRA

TTOO

TWOU

VIAV

VSTM

WISH

Shares of  Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results.

Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1.

Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

SeaStar Medical Holding Corporation - Common Stock

SeaStar Medical Holding Corp

SeaStar Medical Holding Corporation - Warrant

ICU Medical Inc

Stifel analyst Steven Wieczynski maintains Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) with a Buy and lowers the price target from $67 to $54.

Price Target

Analyst Ratings

Stifel Maintains Buy on Caesars Entertainment, Lowers Price Target to $54

Dividends

RWAY

Runway Growth Finance Declared Q2 Supplemental Dividend Of $0.07

Biotech

General

CTMX

CytomX Therapeutics To Provide An Initial CX-904 Phase 1a Clinical Data Update On May 8, 2024

Stifel analyst Chris O'Cull maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Buy and raises the price target from $55 to $62.

Stifel Maintains Buy on Brinker International, Raises Price Target to $62

Contracts

SABR

Sabre Hospitality Announces Multi-Year Renews Wyndham

Elon Musk, the influential tech mogul, has yet to watch the Emmy-nominated documentary &#8220;Return to Space,&#8221; which centers on his company SpaceX&#8217;s mission.
What Happened: On Wednesday, Musk responded to a post by a user on X, Dima Zeniuk, who praised the documentary.
Musk replied, &#8220;Haven't seen it yet.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Haven't seen it yet
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1785462090192318697?ref_src=twsrc%5Etfw">May 1, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38479312/watershed-moment-says-tesla-analyst-as-elon-musk-makes-surprise-china-visit-to-repo?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Watershed Moment,&#8217; Says Tesla Analyst As Elon Musk Makes Surprise China Visit To Reportedly Discuss FSD Rollout And Data Transfer Overseas</a>
Why It Matters: The documentary &#8220;Return to Space&#8221; was <a href="https://www.benzinga.com/general/entertainment/22/07/28102232/netflix-spacex-doc-nominated-for-an-emmy-heres-the-award-it-could-win">nominated for an Emmy Award in 2023</a> for &#8220;Outstanding Music Composition for a Documentary Series or Special (Original Dramatic Score).&#8221; The series focuses on SpaceX&#8217;s mission to send NASA astronauts back to the International Space Station. 
SpaceX, founded by Musk, has played a pivotal role in U.S. space exploration. Prominent biographer Walter Isaacson stated that Musk is the <a href="https://www.benzinga.com/general/24/04/38355446/elon-musk-is-the-only-person-able-to-get-us-astronauts-to-orbit-nasa-can-no-longer-do-it-boeing-cant">only person capable of launching U.S. astronauts</a> into orbit, a task that neither NASA nor Boeing Co. can accomplish. 
Furthermore, Musk has <a href="https://www.benzinga.com/news/24/01/36705685/spacex-ceo-eyes-space-stations-on-mars-and-moon-before-even-one-succesful-starship-flight">ambitious plans for SpaceX,</a> including building space stations on Mars and the Moon. He aims to build a self-sustaining city on Mars by delivering a sufficient payload to the planet with SpaceX&#8217;s Starship launch vehicle. 
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38515667/elon-musk-has-tears-of-laughter-as-tesla-investor-says-stock-is-up-one-gordon-johns?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Has Tears Of Laughter As Tesla Investor Says Stock Is &#8216;Up One Gordon Johnson&#8217; After Bear-Defying Surge</a>
Image via Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Entertainment

SPACE

Elon Musk Says He Has Not Watched Emmy-Nominated Documentary About His Ambitious Space Plans: 'Haven't Seen It Yet'

Barclays analyst Ross Sandler maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Overweight and raises the price target from $220 to $230.

AMZN

Barclays Maintains Overweight on Amazon.com, Raises Price Target to $230

Stifel analyst David Pang maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $65 to $85.

Stifel Maintains Buy on AppLovin, Raises Price Target to $85

<a href="https://www.nbcnews.com/business/personal-finance/prosecutors-examining-transactions-block-owner-cash-app-squarc-rcna147181" title="https://www.nbcnews.com/business/personal-finance/prosecutors-examining-transactions-block-owner-cash-app-squarc-rcna147181">https://www.nbcnews.com/business/personal-finance/prosecutors-examining-transactions-block-owner-cash-app-squarc-rcna147181</a>

'Federal Prosecutors Are Examining Financial Transactions At Block, Owner Of Cash App And Square' - NBC

ELAB

Elevai Labs Acquires Exclusive License To Two Myostatin Muscle Loss Prevention Assets, Announces Plan To Develop In Combination With GLP-1 Obesity Treatments

Stifel analyst Mark Kelley maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $224 to $228.

Stifel Maintains Buy on Amazon.com, Raises Price Target to $228

Like Meta Platforms (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>), Snap Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snap#NYSE">SNAP</a>) and Google parent Alphabet (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goog#NASDAQ">GOOG</a>)(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>),&nbsp;&nbsp;Amazon.com Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) reported better-than-expected quarterly results, with stronger than expected revenue being the result of the improvements on the ad business front.
<h3>First Quarter Highlights</h3>
In part due to its booming&nbsp;AWS division and its advertising service, Amazon reported&nbsp;revenue grew&nbsp;12.52%&nbsp;YoY to $143.3 billion,&nbsp;surpassing LSEG&rsquo;s estimate of&nbsp;$142.5 billion.&nbsp;Operating income&nbsp;far outpaced revenue growth as well as it&nbsp;soared more than 200%&nbsp;to&nbsp;$15.3 billion, which is the first&nbsp;sign that Amazon&rsquo;s cost-cutting initiatives&nbsp;and efficiency improvements are benefiting the bottom line as net income&nbsp;skyrocketed 229% YoY to&nbsp;$10.43&nbsp;billion,&nbsp;with diluted EPS amounting to&nbsp;98 cents a share, surpassing LSEG&rsquo;s estimate of&nbsp;83 cents.
Amazon&rsquo;s businesses are thriving, beginning with party seller services that cover commissions that Amazon collects, along with&nbsp;fulfillment, shipping fees and other charges, grew&nbsp;16%&nbsp;YoY&nbsp;to $34.5 billion.
AWS&nbsp;continues to grow and challenge Google and Microsoft, both the cloud and AI front.
The&nbsp;AWS division&nbsp;reported a&nbsp;17%&nbsp;YoY growth&nbsp;to $25 billion, surpassing StreetAccount&rsquo;s estimate of&nbsp;$24.5 billion&nbsp;and reflecting Amazon&rsquo;s strong positioning compared to its AI rivals,&nbsp;Microsoft&nbsp;Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>), who secured a leadership position with its early entry and OpenAI acquisition,&nbsp;and Alphabet, with the latter finally catching up to its peers in their efforts&nbsp;to lead&nbsp;the way&nbsp;into the golden age of&nbsp;AI.
AWS&rsquo; actions could spell trouble for Alphabet and Microsoft as&nbsp;Jassy&nbsp;revealed&nbsp;significant investments over the next few years to build new infrastructure and data centers.&nbsp;Amazon will be&nbsp;investing&nbsp;$5.3 billion in Saudi Arabia and $5 billion in Mexico&nbsp;to&nbsp;build new infrastructure centers, along with&nbsp;$10 billion&nbsp;in Mississippi&nbsp;to build two data centers&nbsp;that&nbsp;are projected to create at least 1,000 jobs.
Advertising continues to grow, becoming an increasingly important profit driver.&nbsp;
Advertising revenue grew 24%&nbsp;to $11.8 billion, outpacing&nbsp;both&nbsp;retail and cloud computing&nbsp;growth, as well as StreetAccount&rsquo;s estimate of $11.7 billion.&nbsp;This is&nbsp;the first report since&nbsp;Amazon&nbsp;introduced ads&nbsp;in Prime Video,&nbsp;which analysts expect to generate&nbsp;significant revenue over time.&nbsp;Despite being new to the ad business, Amazon has emerged as one of the big players in the online advertising arena. CEO&nbsp;Andy Jassy&nbsp;has made it clear that the e-commerce and cloud titan will continue to focus on its ad efforts, as it plans&nbsp;include more of its sponsored content on its Prime Video platform.
First quarter results across the board show that online ads have rebounded. Last week, Alphabet also announced its ad business reaccelerated after a tough 2022 and 2023.&nbsp;Google reported total ad sales rose&nbsp;from last year&rsquo;s comparable quarter, when they amounted to&nbsp;$54.55 billion,&nbsp;to&nbsp;$61.66 billion.&nbsp;
<h3>Second Quarter Outlook</h3>
Amazon&nbsp;expects&nbsp;profitability&nbsp;growth to continue in the current&nbsp;quarter but at a more measured pace&nbsp;as it guided for an&nbsp;operating income&nbsp;between&nbsp;$10 billion&nbsp;and&nbsp;$14 billion, on the back of revenue in the range between&nbsp;$144 billion to $149 billion, translating to revenue growth in the range between&nbsp;7%&nbsp;and&nbsp;11%.&nbsp;
Amazon&rsquo;s disciplined focus on efficiency is showing results.
Cost-cutting across the board, fulfillment operations tweaks and stabilization of cloud spending all partially contributed to the&nbsp;earnings growth&nbsp;as Amazon focused to&nbsp;grow&nbsp;its most&nbsp;profitable services, including&nbsp;advertising, cloud computing, Prime memberships and its third-party marketplace.
Amazon continues to stand out among its Big Tech peers as it is yet&nbsp;to implement a quarterly dividend. In February,&nbsp;Meta announced&nbsp;its first dividend&nbsp;at&nbsp;50 cents a share. Last week, Alphabet followed the footsteps of Meta as it announced its first ever&nbsp;dividend of 20 cents a share.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

GOOG

GOOGL

MSFT

SNAP

Amazon's Smashing Q1 Financials Show The Power Of A Good And Well Executed Strategy

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is set to report second-quarter earnings on Thursday<a href="https://www.benzinga.com/calendars/earnings?tickers=AAPL"> after market hours</a>.
Wall Street expects $1.40 in earnings per share (EPS), and $84.12 billion in revenue. That&#8217;s down from the $1.52 in EPS and $94.84 billion in revenue, reported for the same quarter, last year. 
Despite recent challenges, Apple&#8217;s strong track record of beating earnings expectations could offer some optimism for investors.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38540655/wall-street-braces-for-brutal-apple-earnings-but-top-analyst-gives-6-reasons-to-sta">Wall Street Braces For Brutal Apple Earnings, But Top Analyst Gives 6 Reasons To Stay Bullish On iPhone Maker</a>
<h2 class="wp-block-heading">Analyst Suggests &#8216;Buying The Fear&#8217;</h2>
Apple stock is down 11.53% year-to-date, weighed down by a weak iPhone 15 cycle.
Bernstein analyst Toni Sacconaghi suggests &#8220;buying the fear&#8221; in Apple stock, anticipating a strong iPhone 16 cycle.
Analysts await updates on iPhone sales, services revenue, and capital return plans from Apple&#8217;s Q2 report. For the next few quarters, also under watch would be Apple Vision Pro headset sales and potential AI advancements.
Let&#8217;s look at what the charts indicate for Apple stock, and how the stock currently maps against Wall Street estimates.
<h2 class="wp-block-heading">Apple Stock&#8217;s Bearish Setup Ahead Of Q2 Earnings&nbsp;</h2>
Charts indicate that the current trend for Apple stock is relatively stagnant with selling pressure, indicating bearish market momentum towards the stock. However, there are certain green shoots emerging among the oscillators for Apple bulls.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="625" height="454" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/01080518/Screenshot-2024-05-01-at-5.34.46-PM.png" alt="" class="wp-image-317258" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/01080518/Screenshot-2024-05-01-at-5.34.46-PM.png 625w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/01080518/Screenshot-2024-05-01-at-5.34.46-PM-300x218.png 300w" sizes="(max-width: 625px) 100vw, 625px" /></figure>
<a target="_blank" href="https://pro.benzinga.com/dashboard" rel="noreferrer noopener">Chart: Benzinga Pro</a>
The stock price is currently at $170.01. That&#8217;s above the eight-day simple moving average (SMA) of $169.35 and the 20-day SMA of $169.64, suggesting positive momentum. 
However, Apple stock is below the 50-day SMA of $172.61 and significantly below the 200-day SMA of $181.47, both indicating a bearish signal. 
The exponential moving averages (EMA) are presenting mixed signals as well.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="625" height="454" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/01081033/Screenshot-2024-05-01-at-5.40.13-PM.png" alt="" class="wp-image-317270" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/01081033/Screenshot-2024-05-01-at-5.40.13-PM.png 625w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/01081033/Screenshot-2024-05-01-at-5.40.13-PM-300x218.png 300w" sizes="(max-width: 625px) 100vw, 625px" /></figure>
<a target="_blank" href="https://pro.benzinga.com/dashboard" rel="noreferrer noopener">Chart: Benzinga Pro</a>
Additionally, the Moving Average Convergence Divergence (MACD) indicator is -0.80, indicating bearishness. 
The MACD line has been treading upwards recently and has also crossed over the signal line. When the MACD line crosses from below to above the signal line, the indicator is considered bullish. The further below the zero line the stronger the signal.
The Relative Strength Index (RSI) of 48.16 suggests the stock is in the Neutral territory. The Bollinger Bands have been trying to keep Apple stock price within the lower (bearish). However, the stock has recently crossed over to the upper (bullish) bollinger band, suggesting positive momentum scoring over negative. 
Overall, the technical indicators for Apple stock suggest a bearish trend. Clearly, investors are not &#8220;buying the fear,&#8221; yet. 
Oscillators suggest there is the potential for bulls to take over if positive market momentum sustains.
<h2 class="wp-block-heading">Apple Analysts Consensus Points To 20% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/AAPL/analyst-ratings"> The consensus analyst rating</a> on Apple stock stands at an Outperform currently with a price target of $196.77 a share. The more recent analyst reviews on the stock, April 22 onwards, came from Citigroup, Bernstein, and Morgan Stanley. These three firms have an average price target of $205 per share, implying a 20.62% upside for Apple stock.
Upcoming events include a May 7 product launch event and WWDC on June 10 may serve as catalysts for Apple stock over the near-term. Analysts are anticipating further insights into Apple&#8217;s AI plans at these events. Apple&#8217;s underperformance has been linked by many to its AI lag. Hence, expectations for AI progress at WWDC could boost investor confidence.
AAPL Price Action: Apple stock closed the trading day, Tuesday, at $170.33, down 1.83% for the day.
Read Next: <a href="https://www.benzinga.com/news/econ-s/24/05/38548716/private-employment-increases-by-192-000-beats-forecasts-hiring-was-broad-based-in-april">Private Employment Increases By 192,000, Beats Forecasts: &#8216;Hiring Was Broad-Based In April&#8217;</a>

Analyst Color

Earnings

Technicals

Previews

Tech

AAPL

Apple Chart Suggests Investors Aren't 'Buying The Fear': iPhone, AI Expectations In Focus For Q2

Stifel analyst Craig Jones maintains Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) with a Hold and lowers the price target from $8 to $7.

Stifel Maintains Hold on Agilon Health, Lowers Price Target to $7

CETX

Cemtrex Prices Upsized Offering For Gross Proceeds Of $10M

Stifel analyst Daniel Arias maintains 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Buy and lowers the price target from $63 to $53.

Stifel Maintains Buy on 10x Genomics, Lowers Price Target to $53

During the last three months, 4 analysts shared their evaluations of UFP Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPI#NASDAQ">UFPI</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated UFP Industries and provided 12-month price targets. The average target is $124.25, accompanied by a high estimate of $137.00 and a low estimate of $102.00. Surpassing the previous average price target of $124.00, the current average has increased by 0.2%.
<img src="https://www.benzinga.com/files/images/story/2024/1714568500_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of UFP Industries's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reuben Garner</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$133.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$102.00</td>
<td>-</td>
</tr>
<tr>
<td>Reuben Garner</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Stanley Elliott</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to UFP Industries. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of UFP Industries compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for UFP Industries's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into UFP Industries's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UFPI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on UFP Industries analyst ratings.</a>
<h2>Get to Know UFP Industries Better</h2>
UFP Industries Inc is a supplier of lumber to the manufactured housing industry. Today UFP Industries is a multibillion-dollar holding company with subsidiaries around the globe that serve three markets: retail, packaging and construction.
<h3>Unraveling the Financial Story of UFP Industries</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: UFP Industries's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -20.35%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: UFP Industries's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 6.44%, the company may face hurdles in effective cost management.
Return on Equity (ROE): UFP Industries's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.32%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): UFP Industries's ROA stands out, surpassing industry averages. With an impressive ROA of 2.45%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.13, UFP Industries adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UFPI

Evaluating UFP Industries: Insights From 4 Financial Analysts

NHTC

Natural Health Trends Q1 2024 EPS $0.02 Inline With $0.02 YoY; Revenue $11M Down From $11.9M YoY

MBRX

Moleculin Announces Formation Of Scientific Advisory Board To Support Development Of Annamycin

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Northern Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $47.42, a high estimate of $56.00, and a low estimate of $38.00. Surpassing the previous average price target of $47.20, the current average has increased by 0.47%.
<img src="https://www.benzinga.com/files/images/story/2024/1714568478_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Northern Oil &amp; Gas. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Derrick Whitfield</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$56.00</td>
<td>$58.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Northern Oil &amp; Gas. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Northern Oil &amp; Gas compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Northern Oil &amp; Gas's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Northern Oil &amp; Gas's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NOG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Northern Oil &amp; Gas analyst ratings.</a>
<h2>Discovering Northern Oil &amp; Gas: A Closer Look</h2>
Northern Oil &amp; Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. Company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), and the Appalachian Basin (Pennsylvania and Ohio).
<h3>Northern Oil &amp; Gas: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Northern Oil &amp; Gas displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 22.55%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Northern Oil &amp; Gas's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 71.2% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Northern Oil &amp; Gas's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 22.51% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Northern Oil &amp; Gas's ROA excels beyond industry benchmarks, reaching 8.85%. This signifies efficient management of assets and strong financial health.
Debt Management: Northern Oil &amp; Gas's debt-to-equity ratio stands notably higher than the industry average, reaching 0.9. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Northern Oil & Gas

These Healthcare stocks are trading higher:-Iovance Biotherapeutics Inc (IOVA) stock is trading at $12.08, a gain of $2.93, or 31.75%, on high volume.  Iovance Biotherapeutics Inc. gets a Sentiment Score of Very Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target

Healthcare Stocks Moving Tuesday: IOVA, GRYP, OCGN, ICU, RAPT, SMMT, UPC, NNOX

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Despite a recent decline in the leading economic index, the U.S. economy is positioned for a positive future in 2024. Strong employment and robust stock levels contribute to the optimistic outlook. And, while there may be a slowdown in GDP growth in the second and third quarters, the U.S. Federal Reserve&rsquo;s forecast of 2.9% growth in the first quarter. This indicates a resilient and promising economic landscape for the United States. These top <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> will benefit from this strong economy, invest now.



<h2>SeaStar Medical (ICU)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/research-lab-1600-300x169.jpg" alt="Scientist using a microscope"><div>Source: Maksim Shmeljov / Shutterstock.com</div></div>


SeaStar Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/icu-stock-quote/">ICU</a>) is a biotechnology company that focuses on treating excessive inflammation by using extracorporeal therapies.



The biotechnology industry is expected to surpass a value of <a href="https://www.globenewswire.com/en/news-release/2024/02/07/2825408/0/en/Global-Biotechnology-Market-to-Surpass-USD-3879-51-billion-by-2030-Driven-by-Increasing-Prevalence-of-Chronic-Diseases.html">3879.51 billion dollars</a> by 2030, for a CAGR of 13.9%. The primary driver of growth for the industry is the amount of chronic diseases, genetic abnormalities and targeted diseases affecting the population. As a result, it is more important than ever to be able to utilize technology to treat them.



SeaStar&rsquo;s income and revenue have not turned out so well. Its income has <a href="https://www.wsj.com/market-data/quotes/ICU/financials/annual/income-statement">shrunk by 400% </a>over the last year. However, it has dedicated more money to research, with its SGA growing by 111.71% in 2022. Additionally, SeaStar&rsquo;s key catalyst will allow the company to become much more profitable than it currently is.



The firm&rsquo;s key catalyst is its exciting potential for revenue through its newest product. SeaStar&rsquo;s Selective Cytopheretic Device has <a href="https://www.medicaldevice-network.com/news/seastars-selective-cytopheretic-device-wins-fda-breakthrough-designation/">met the requirements</a> to be considered a Humanitarian Device Exemption by the U.S. Food and Drug Administration and is expecting approval soon.



In conclusion, Seastar Medical is one of the rare powerful penny stocks with profit potential.



<h2>Adverum Biotechnologies (ADVM)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/lab-300x169.jpg" alt="Scientists in a lab"><div>Source: Matej Kastelic / Shutterstock</div></div>


Adverum Biotechnologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/advm-stock-quote/">ADVM</a>) is a gene therapy company targeting medical needs for ocular and rare diseases. It is valued at $1.97, marking a YTD increase of more than 130%.



ADVM has shown ample <a href="https://companiesmarketcap.com/adverum-biotechnologies/marketcap/">revenue growth</a> of 169.66% from $76.05 million in 2023 to $200 million in 2024. ADVM also boasts an impressive <a href="https://seekingalpha.com/symbol/ADVM/valuation/metrics">price to sales ratio</a> of 56.67 and capex to sales of 22.25%. Both figures surpass the sector medians. These financials indicate that Adverum is quickly rising, indicating an elevated stock price in the foreseeable future.



Adverum is <a href="https://www.accesswire.com/795981/10-biotech-stocks-below-cash-value-with-key-catalysts-on-the-horizon-an-analysis">undergoing</a> the LUNA trials which aim to evaluate the safety and efficacy of various products. Once this data is announced work can be continued on their flagship products leading to an increase in efficiency and eventual profits. The data could potentially be a breakthrough in gene therapy and all eyes are on ADVM to see if it can capitalize. All of these factors make ADVM one of the top penny stocks to keep an eye on.



<h2>Grab Holdings (GRAB)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1922313167-300x169.png" alt="Motorcycle helmet with Grab logo on a motorcycle parked at the road side"><div>Source: Nor Sham Soyod / Shutterstock.com</div></div>


Grab Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/grab-stock-quote/">GRAB</a>) is a Malaysian technology company that specializes in services throughout Southeast Asia such as ride-hailing, food delivery and digital payments. Its stock is <a href="https://finance.yahoo.com/quote/GRAB">up nearly 5% YTD at $3.45</a>.



GRAB has reported strong financials in the year 2023. Particularly in their report for Q3 2023, its revenue grew to <a href="https://investors.grab.com/news-releases/news-release-details/grab-reports-third-quarter-2023-results">$615 million, marking a 61%</a> increase year-over-year. Additionally, the company announced its first positive EBITDA quarter, which grew to <a href="https://investors.grab.com/news-releases/news-release-details/grab-reports-third-quarter-2023-results">$29 million</a>. This resulted in a 71% improvement YOY in losses.&nbsp;



GRAB is still not profitable yet because it prioritizes growth, similar to Amazon&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzn-stock-quote/">AMZN</a>) and Uber&rsquo;s (NYSE:<a href="https://investorplace.com/stock-quotes/uber-stock-quote/">UBER</a>) business models. However, given its current growth, it could report positive quarterly earnings in 2024 or even its upcoming report of Q4 of 2023. As one of the largest tech companies in SE Asia, this stock is one of the top penny stocks on the market.&nbsp;



On the date of publication, Michael Que did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



The researchers contributing to this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Michael Que is a financial writer with extensive experience in the technology industry, with his work featured on Seeking Alpha, Benzinga and MSN Money. He is the owner of Que Capital, a research firm that combines fundamental analysis with ESG factors to pick the best sustainable long-term investments.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/02/unleash-massive-returns-with-these-3-top-penny-stocks/">Unleash Massive Returns With These 3 Top Penny Stocks</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Unleash Massive Returns With These 3 Top Penny Stocks

SeaStar Medical Holding (ICU) has released an update. SeaStar Medical Holding Corporation has announced that the FDA has approved their Selective C...

SeaStar Medical's Pediatric Device Wins FDA Approval

These Healthcare stocks are trading higher:-Vincerx Pharma Inc (VINC) stock is trading at $3.88, a gain of $0.81, or 26.22%, on high volume.  Vincera Pharma Inc gets a Sentiment Score of Neutral from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $4.00.  -Ocular Therap

Healthcare Stocks Making Moves Thursday: VINC, OCUL, AMLX, NVAX, ACON, ICU, LUNG, NERV

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!



Moving socks this morning are earnings reports, a moon mission and more.



Let&rsquo;s jump into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Beneficient (NASDAQ:<a href="https://investorplace.com/stock-quotes/benf-stock-quote/">BENF</a>) stock is rocketing more than 87% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318093101&amp;type=PDF&amp;symbol=BENF&amp;cdn=fb42ce62102f65e5ea4f3bfd912982e9&amp;companyName=Beneficient&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-02-22">alongside insider buying</a>.</li>



<li>Telesis Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/tbio-stock-quote/">TBIO</a>) shares are soaring over 59% with heavy pre-market trading.</li>



<li>SU Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/sugp-stock-quote/">SUGP</a>) stock is surging more than 55% with strong early morning trading.</li>



<li>Intuitive Machines (NASDAQ:<a href="https://investorplace.com/stock-quotes/lunr-stock-quote/">LUNR</a>) shares are rising over 47% after <a href="https://www.cnbc.com/2024/02/22/intuitive-machines-lunr-im-1-moon-landing-for-nasa.html">landing on the moon</a>.</li>



<li>Carvana (NYSE:<a href="https://investorplace.com/stock-quotes/cvna-stock-quote/">CVNA</a>) stock is increasing more than 30% after <a href="https://www.cnbc.com/2024/02/22/carvana-shares-soar-after-company-says-it-expects-core-profit-over-100-million-in-q1.html">reporting its first profit</a>.</li>



<li>Maravai LifeSciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrvi-stock-quote/">MRVI</a>) shares are increasing over 21% with the release of its <a href="https://www.nasdaq.com/press-release/maravai-lifesciences-reports-fourth-quarter-and-full-year-2023-financial-results-2024">Q4 earnings report</a>.</li>



<li>AXT (NASDAQ:<a href="https://investorplace.com/stock-quotes/axti-stock-quote/">AXTI</a>) stock is gaining more than 16% after releasing <a href="https://finance.yahoo.com/news/axt-inc-announces-fourth-quarter-210500009.html">Q4 earnings results</a>.</li>



<li>Block (NYSE:<a href="https://investorplace.com/stock-quotes/sq-stock-quote/">SQ</a>) shares are jumping over 15% after <a href="https://www.cnbc.com/2024/02/22/block-sq-earnings-q4-2023.html">reporting a surprise profit</a>.</li>



<li>Nexalin Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxl-stock-quote/">NXL</a>) stock is heading more than 14% higher without any clear news.</li>



<li>Sleep Number (NASDAQ:<a href="https://investorplace.com/stock-quotes/snbr-stock-quote/">SNBR</a>) shares are up over 13% with a <a href="https://www.marketwatch.com/story/sleep-number-loses-less-money-than-wall-street-feared-and-stock-rallies-fe0b5f49">narrower-than-expected loss</a>.</li>
</ol><h2>Top 10 Losers</h2>



<ol><li>Charge Enterprises (NASDAQ:<a href="https://investorplace.com/stock-quotes/crge-stock-quote/">CRGE</a>) stock is plummeting more than 44% after <a href="https://finance.yahoo.com/news/charge-enterprises-announces-decision-nasdaq-211500564.html">getting a delisting notice</a>.</li>



<li>Applied Optoelectronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/aaoi-stock-quote/">AAOI</a>) shares are diving over 41% with the <a href="https://finance.yahoo.com/news/applied-optoelectronics-reports-fourth-quarter-211000668.html">release of earnings and other news</a>.</li>



<li>Sequans Communications (NYSE:<a href="https://investorplace.com/stock-quotes/sqns-stock-quote/">SQNS</a>) stock is tumbling more than 29% after <a href="https://www.businesswire.com/news/home/20240222683486/en/Renesas-Announces-Termination-of-Memorandum-of-Understanding-and-Tender-Offer-for-Proposed-Acquisition-of-Sequans">terminating a plan for a tender offer</a>.</li>



<li>SeaStar Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/icu-stock-quote/">ICU</a>) shares are taking a 23% beating after getting <a href="https://www.marketwatch.com/story/seastar-medical-shares-rise-10-after-fda-humanitarian-device-exemption-approval-f95d358c">approval for a pediatric device</a>.</li>



<li>Ambow Education (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ambo-stock-quote/">AMBO</a>) stock is dropping over 22% this morning.</li>



<li>Ascent Solar Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/asti-stock-quote/">ASTI</a>) shares are decreasing more than 20% after announcing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318094531&amp;type=PDF&amp;symbol=ASTI&amp;cdn=ba960a315d2fd52ed2f17c87bee46b40&amp;companyName=Ascent+Solar+Technologies+Inc&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-02-23">proposed public offering</a>.</li>



<li>Infobird (NASDAQ:<a href="https://investorplace.com/stock-quotes/ifbd-stock-quote/">IFBD</a>) stock is sliding over 15% as it prepares for a <a href="https://www.nasdaq.com/press-release/infobird-co.-ltd-announces-1-for-8-share-consolidation-and-capital-reduction-2024-02">reverse stock split</a>.</li>



<li>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) shares are slipping more than 15% this morning.</li>



<li>Indie Semiconductor (NASDAQ:<a href="https://investorplace.com/stock-quotes/indi-stock-quote/">INDI</a>) stock is dipping close to 15% with its <a href="https://www.businesswire.com/news/home/20240222697156/en/indie-Semiconductor-Achieves-Record-Fourth-Quarter-and-2023-Results">latest earnings release</a>.</li>



<li>Fox Factory (NASDAQ:<a href="https://investorplace.com/stock-quotes/foxf-stock-quote/">FOXF</a>) shares close out our pre-market stock movers down over 14% after <a href="https://in.investing.com/news/fox-factory-earnings-missed-by-073-revenue-topped-estimates-4031845">missing earnings estimates</a>.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



<ol><li>
</ol><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/02/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-feb-23rd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

TCTM, BMR and HOLO among pre-market losers

CPOP, PMEC and ARIZ among mid-day movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
SeaStar Medical Holding (NASDAQ:<a href="https://investorplace.com/stock-quotes/icu-stock-quote/">ICU</a>) just reported results for the fourth quarter of 2023.<ul><li>SeaStar Medical Holding reported earnings per share of -19 cents. This was below the analyst estimate for EPS of -13 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/icu-stock-earnings-seastar-medical-holding-for-q4-of-2023/">ICU Stock Earnings: SeaStar Medical Holding Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ICU Stock Earnings: SeaStar Medical Holding Misses EPS for Q4 2023

SeaStar Medical Holding GAAP EPS of -$1.21 misses by $0.60

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Thursday morning!



Moving stocks this morning are earnings reports, shareholder meetings, public offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Tian Ruixiang (NASDAQ:<a href="https://investorplace.com/stock-quotes/tirx-stock-quote/">TIRX</a>) stock is rocketing more than 151% after announcing plans for an <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318240834&amp;type=PDF&amp;symbol=TIRX&amp;cdn=28383035430ee99a000270a0a49b5cf7&amp;companyName=TIAN+RUIXIANG+Holdings+Ltd&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-04-17">extraordinary general shareholders meeting</a>.</li>



<li>MicroCloud Hologram (NASDAQ:<a href="https://investorplace.com/stock-quotes/holo-stock-quote/">HOLO</a>) shares are soaring over 52% alongside heavy pre-market trading.</li>



<li>Secoo (NASDAQ:<a href="https://investorplace.com/stock-quotes/seco-stock-quote/">SECO</a>) stock is surging more than 32% with strong early morning trading.</li>



<li>Smart for Life (NASDAQ:<a href="https://investorplace.com/stock-quotes/smfl-stock-quote/">SMFL</a>) shares are rising over 23% after announcing it will <a href="https://www.nasdaq.com/press-release/smart-for-life-to-sponsor-industry-event-whats-up-with-supps-at-supplyside-east-2024">sponsor an upcoming event</a>.</li>



<li>Tenax Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/tenx-stock-quote/">TENX</a>) stock is gaining 17% on Thursday morning.</li>



<li>Earlyworks (NASDAQ:<a href="https://investorplace.com/stock-quotes/elws-stock-quote/">ELWS</a>) shares are increasing more than 16% despite a lack of news this morning.</li>



<li>Citius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctxr-stock-quote/">CTXR</a>) stock is climbing over 16% without any apparent news on Thursday.</li>



<li>ReTo Eco-Solutions (NASDAQ:<a href="https://investorplace.com/stock-quotes/reto-stock-quote/">RETO</a>) shares are heading more than 15% higher this morning.</li>



<li>CERo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/">CERO</a>) stock is jumping over 14% with no obvious news to report.</li>



<li>Bruush Oral Care (NASDAQ:<a href="https://investorplace.com/stock-quotes/brsh-stock-quote/">BRSH</a>) shares are up more than 13% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Semilux International (NASDAQ:<a href="https://investorplace.com/stock-quotes/selx-stock-quote/">SELX</a>) stock is crashing over 43% with no obvious news this morning.</li>



<li>Canaan (NASDAQ:<a href="https://investorplace.com/stock-quotes/can-stock-quote/">CAN</a>) shares are plummeting more than 28% after releasing its <a href="https://www.nasdaq.com/press-release/canaan-inc.-files-2023-annual-report-on-form-20-f-2024-04-17">2023 annual report</a>.</li>



<li>NRX Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/nrxp-stock-quote/">NRXP</a>) stock is diving over 24% on a <a href="https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-announces-proposed-underwritten-public-offering-of-common-stock-302120123.html">proposed public offering</a>.</li>



<li>Trilogy Metals (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tmq-stock-quote/">TMQ</a>) shares are tumbling more than 22% on an <a href="https://investorplace.com/2024/04/why-is-trilogy-metals-tmq-stock-down-29-today/">Ambler Access Project update</a>.</li>



<li>Lithium Americas (NYSE:<a href="https://investorplace.com/stock-quotes/laac-stock-quote/">LAAC</a>) stock is taking an over 20% beating on <a href="https://seekingalpha.com/news/4090749-lithium-americas-sinks-on-plans-for-55m-share-offering?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain">plans for a share offering</a>.</li>



<li>Soligenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) shares are falling more than 20% <a href="https://investorplace.com/2024/04/why-is-soligenix-sngx-stock-up-58-today/">following a recent rally</a>.</li>



<li>Reliance Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) stock is dropping over 19% on Thursday morning.</li>



<li>Trio Petroleum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tpet-stock-quote/">TPET</a>) shares are decreasing close to 17% as it <a href="https://investorplace.com/2024/04/why-is-trio-petroleum-tpet-stock-down-22-today/">continues recent negative movement</a>.</li>



<li>iLearningEngines (NASDAQ:<a href="https://investorplace.com/stock-quotes/aile-stock-quote/">AILE</a>) stock is declining 15% today.</li>



<li>SeaStar Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/icu-stock-quote/">ICU</a>) shares close out our pre-market stock movers down more than 14% with the release of its <a href="https://www.nasdaq.com/press-release/seastar-medical-reports-2023-financial-results-and-provides-a-business-update-2024-04">2023 financial results</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-april-18th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

SeaStar Medical Holding Stock (NASDAQ:ICU), Short Interest Report

People Also Watch